Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RetiSpec has developed a non-invasive diagnostic platform using hyperspectral retinal imaging combined with artificial intelligence to detect early signs of Alzheimer’s disease by identifying amyloid beta protein signatures in the retina. The company’s device and software are undergoing pivotal studies to support FDA clearance. Early results show strong correlation between their test and PET brain amyloidosis status, supporting its use as a scalable screening tool for preclinical Alzheimer’s detection. Commercialization activities are ongoing with recent funding secured to advance regulatory approval and market launch.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RetiSpec.